BioNTech SE - ADR Forecast, price target & analysts
BioNTech SE - ADR Target price 2025 - Analyst rating & recommendation
BioNTech SE - ADR Classifications & Recommendation:
BioNTech SE - ADR Price Target
| Target Price | $143.75 |
| Price | $108.78 |
| Potential |
32.15%
register free of charge
|
| Number of Estimates | 20 |
|
20 Analysts have issued a price target BioNTech SE - ADR 2026 .
The average BioNTech SE - ADR target price is $143.75.
This is
32.15%
register free of charge
$176.85
62.57%
register free of charge
$121.11
11.34%
register free of charge
|
|
| A rating was issued by 23 analysts: 18 Analysts recommend BioNTech SE - ADR to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the BioNTech SE - ADR stock has an average upside potential 2026 of
32.15%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Billion $ | 4.13 | 2.78 |
| 77.31% | 32.57% | |
| EBITDA Margin | 28.52% | -40.93% |
| 67.77% | 243.52% | |
| Net Margin | 24.27% | -26.32% |
| 54.80% | 208.44% |
21 Analysts have issued a sales forecast BioNTech SE - ADR 2024 . The average BioNTech SE - ADR sales estimate is
This results in the following potential growth metrics:
11 Analysts have issued an BioNTech SE - ADR EBITDA forecast 2024. The average BioNTech SE - ADR EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 BioNTech SE - ADR Analysts have issued a net profit forecast 2024. The average BioNTech SE - ADR net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 4.18 | -3.06 |
| 89.74% | 173.21% | |
| P/E | negative | |
| EV/Sales | 2.77 |
9 Analysts have issued a BioNTech SE - ADR forecast for earnings per share. The average BioNTech SE - ADR <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the BioNTech SE - ADR stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
BioNTech SE - ADR...
Current BioNTech SE - ADR Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Truist Securities |
Locked
➜
Locked
|
Locked | Jan 10 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Dec 11 2024 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Nov 27 2024 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Nov 26 2024 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Nov 19 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 18 2024 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Nov 18 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Truist Securities:
Locked
➜
Locked
|
Jan 10 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Dec 11 2024 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Nov 27 2024 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Nov 26 2024 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Nov 19 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 18 2024 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Nov 18 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
